Stay updated on Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.

Latest updates to the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to the study details or page functionality.SummaryDifference0.1%

- Check26 days agoChange DetectedRevision updated: v3.4.2 removed; v3.4.3 added.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded site revision tag Revision: v3.4.2 and removed an operating-status notice (lapse in government funding) along with Revision: v3.4.1. The core study details, eligibility criteria, and trial information remain unchanged.SummaryDifference0.5%

- Check62 days agoChange DetectedA site-wide status notice regarding government funding and NIH operating status was added, and the page version updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check69 days agoChange DetectedAdded a glossary to clarify trial terms for readers. Updated QC labeling and metadata indicators, including 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and Revision: v3.4.0.SummaryDifference0.3%

- Check83 days agoChange DetectedRevision from v3.3.3 to v3.3.4 appears as a UI/version label update on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.